Subscribe for unlimited access to DynaMed content, CME/CE & MOC credit, and email alerts on content you follow.

Already subscribed? Sign in now

Learn more about CME

Antiplatelet and Anticoagulant Drugs for Acute Coronary Syndromes

MoreVert
AddCircleOutlineFollow
ShareShare
AddCircleOutlineFollow
Follow
ShareShare
Share

You must be a subscriber to see the full topic content.

  • KeyboardArrowRight

    Overview and Recommendations

    • Background

    • Management

  • Related Summaries

  • Overview

  • KeyboardArrowRight

    Antithrombotic Therapy Recommendations from Professional Organizations

    • KeyboardArrowRight

      American College of Cardiology/American Heart Association (ACC/AHA)

      • Recommendations

      • Algorithm for antithrombotic therapy

    • European Society of Cardiology (ESC)

    • Recommendations for patients with atrial fibrillation (AF)

  • KeyboardArrowRight

    Aspirin

    • Dosing

    • Administration

  • KeyboardArrowRight

    P2Y12 Inhibitors and Dual Antiplatelet Therapy (DAPT)

    • General information

    • KeyboardArrowRight

      Recommendations from professional organizations

      • American College of Cardiology/American Heart Association (ACC/AHA) DAPT guidelines

      • European Society of Cardiology (ESC) DAPT guidelines

      • American College of Chest Physicians (ACCP) guidelines (Ninth Edition)

    • KeyboardArrowRight

      Clopidogrel

      • Efficacy of clopidogrel

      • Dosing of clopidogrel

      • Duration of clopidogrel

      • Proton pump inhibitors and clopidogrel

      • Effect of genetic variants

    • Prasugrel

    • Ticlopidine

    • Ticagrelor

    • Cangrelor

    • Comparative efficacy among P2Y12 inhibitors

  • Other Antiplatelet Drugs

  • KeyboardArrowRight

    Glycoprotein IIb/IIIa Antagonists

    • Dosing

    • Drug class efficacy

    • Tirofiban

    • Eptifibatide

    • Abciximab

    • Oral glycoprotein IIb/IIIa antagonists

  • KeyboardArrowRight

    Anticoagulants

    • KeyboardArrowRight

      Heparin

      • Dosing for acute coronary syndrome

      • Heparin efficacy (drug class)

      • Dalteparin

      • Enoxaparin

      • Nadroparin

    • KeyboardArrowRight

      Direct thrombin inhibitors

      • Parenteral direct thrombin inhibitors

      • Hirudin

      • Bivalirudin

      • Oral direct thrombin inhibitors

    • KeyboardArrowRight

      Fondaparinux

      • Dosing

      • Fondaparinux efficacy

    • Vitamin K antagonists

    • KeyboardArrowRight

      Factor Xa inhibitors

      • Class efficacy for oral Factor Xa inhibitors

      • Rivaroxaban

      • Apixaban

      • Darexaban

      • Otamixaban

      • Other anticoagulant agents

    • Other considerations

  • Use in Chronic Kidney Disease

  • Risk for Bleeding

  • KeyboardArrowRight

    Quality Improvement

    • Physician Quality Reporting System Quality Measures

    • Choosing Wisely Italy

  • KeyboardArrowRight

    Guidelines and Resources

    • KeyboardArrowRight

      Guidelines

      • International guidelines

      • United States guidelines

      • United Kingdom guidelines

      • Canadian guidelines

      • European guidelines

    • Review articles

  • Patient Information

  • KeyboardArrowRight

    ICD Codes

    • ICD-10 codes

  • KeyboardArrowRight

    References

    • General references used

    • Recommendation grading systems used

    • Synthesized Recommendation Grading System for DynaMed

    • DynaMed Editorial Process

    • Special acknowledgements

    • How to cite

Topic Editor
Jinnette Dawn Abbott MD, FACC, FSCAI
KeyboardArrowDown
Affiliations

Professor of Medicine, Brown University; Rhode Island, United States; Director of Interventional Cardiology, Rhode Island Hospital, Miriam Hospital; Rhode Island, United States

Conflicts of Interest

Dr. Abbott declares no relevant financial conflicts of interest.

Recommendations Editor
Zbys Fedorowicz MSc, DPH, BDS, LDSRCS
KeyboardArrowDown
Affiliations

Director of Bahrain Branch of the United Kingdom Cochrane Center, The Cochrane Collaboration; Awali, Bahrain

Conflicts of Interest

Dr. Fedorowicz declares no relevant financial conflicts of interest.

Deputy Editor
Peter Oettgen MD
KeyboardArrowDown
Affiliations

Editor in Chief, DynaMed; Cardiologist, Beth Israel Deaconess Medical Center; Massachusetts, United States; Associate Professor of Medicine, Harvard Medical School; Massachusetts, United States

Conflicts of Interest

Dr. Oettgen declares no relevant financial conflicts of interest.

CheckCircle

top